Practical Neurology

February 2020

Multiple Sclerosis: Reverse Engineering Continues

Featured

The Central Vein Sign

Evanthia Bernitsas, MD

Point/Counterpoint: Neurofilament Light

Adil Javed, MD, PhD, and James Stankiewicz MD, FAAN

Sphingosine-1-Phosphate Modulators for Multiple Sclerosis

Mark B. Skeen, MD

AntiCD20+ Agents

Brian Barry, MD, and Robert K. Shin, MD

Cladribine

Crystal Dixon, MD, Miguel Melo-Bicchi, MD, and Kottil W. Rammohan, MD

Drugs in Development for Multiple Sclerosis

Konstantin Balashov, MD, PhD

Point/Counterpoint: Food and Drug Administration Multiple Sclerosis Categorization Changes

Svetlana Primma Eckert, MD, Bianca Weinstock-Guttman, MD, and Stephen Krieger, MD

Multiple Sclerosis Treatment in Racial and Ethnic Minorities

Michael V. Robers, MD, Deepak Soneji, MD, PhD, and Lilyana Amezcua, MD, MS

In this issue

Guest Medical Editor's Page

Multiple Sclerosis: Reverse Engineering Continues

Thomas P. Leist, MD

Cover Focus

The Central Vein Sign

Is 1.5 T MRI still relevant for diagnosis of multiple sclerosis?

Evanthia Bernitsas, MD

Point/Counterpoint: Neurofilament Light

Ready for prime time as a biomarker for multiple sclerosis or not?

Adil Javed, MD, PhD, and James Stankiewicz MD, FAAN

Sphingosine-1-Phosphate Modulators for Multiple Sclerosis

Sphingosine-1-phosphate modulators may act through more than just inhibition of neuroimmune and neuroinflammatory effects of multiple sclerosis.

Mark B. Skeen, MD

AntiCD20+ Agents

AntiCD20+ agents are among the highest efficacy treatments for multiple sclerosis.

Brian Barry, MD, and Robert K. Shin, MD

Cladribine

Cladribine is an effective oral treatment for multiple sclerosis with potential for long-term remission.

Crystal Dixon, MD, Miguel Melo-Bicchi, MD, and Kottil W. Rammohan, MD

Drugs in Development for Multiple Sclerosis

Stem cells, tyrosine kinase inhibitors, remyelinating agents, metabolically active molecules, and more are being tested as potential new disease-modifying treatments.

Konstantin Balashov, MD, PhD

Point/Counterpoint: Food and Drug Administration Multiple Sclerosis Categorization Changes

Are the changes a step forward or a step back?

Svetlana Primma Eckert, MD, Bianca Weinstock-Guttman, MD, and Stephen Krieger, MD

Multiple Sclerosis Treatment in Racial and Ethnic Minorities

Systematic literature review shows little evidence to guide treatment.

Michael V. Robers, MD, Deepak Soneji, MD, PhD, and Lilyana Amezcua, MD, MS

Special Report

Long-Term Survival Prognosis After Stroke

A practical guide for clinicians.

Robert Shavelle, PhD, FAACPDM; Jordan Brooks, PhD, MPH; David Strauss, PhD, FASA; and Amytis Towfighi, MD

Columns

Headache Horizons: Headaches That Roam the Night

Many headache types can occur in the night, including some that may be exclusive to dream periods.

Peter McAllister, MD

Neuromuscular Notes: Taking the Mis- out of CIDP Diagnosis

Criteria exist for CIDP and should be used for diagnosis and management.

Karissa Gable, MD

Smart Business Great Medicine: Patient Engagement

Let’s make engaging patients worth doing.

James Geyer, MD, and Jenna Cooper, CRNP

About The Cover Artist

An Example of the Central Vein Sign

Daniel S. Reich, MD, PhD

Read Issue

Patients & Caregivers

Find Information and tools about Neurological diseases to assist patients and caregivers.

Visit Page

Students & Residents

Valuable insights and advice for future neurologists.

Visit Page

Case Reports